BIOMM SA ("Company" or "Biomm"), in compliance with the provisions of Instruction of the Brazilian Securities Commission No. 358, of January 3, 2002, as amended, continuing the Notice to the Market dated May 26, 2021, hereby informs its shareholders and the market in general that the National Health Surveillance Agency – ANVISA approved, on this date, the start of phase 3 clinical study of the monoclonal antibody lerionlimab in Brazil.

The clinical trial will be conducted by the Academic Research Organization (ARO) of the Hospital Israelita Albert Einstein (HIAE), in collaboration with CytoDyn, the US company responsible for developing the drug, and BIOMM, exclusive partner for the commercialization of lerionlimab in Brazil.

The trial, which will be carried out in 35 brazilian research centers with 612 patients who are hospitalized and in need of oxygenation support, aims to prevent the disease from evolving into a more severe case, requiring invasive mechanical ventilation.

Lerionlimab acts to prevent an excessive immune system response in patients infected with the new coronavirus, reducing the overproduction of inflammatory cytokines, also known as “cytokine storms”. This inflammatory storm, which significantly aggravates the clinical condition, can often lead to the patient’s death.

The Company will keep its shareholders and the market in general updated on the subject of this material fact.


Biomm S.A.
Mirna Santiago Vieira
Chief Financial and Investor Relations Officer